About this episode
Apr 28
Keeping it Simple: Top 10 Things to Know About the 2026 Dyslipidemia Guideline
The 2026 ACC/AHA Dyslipidemia Guidelines highlight that Lp(a) confers a graded ASCVD risk, with levels around 125 nmol/L (50 mg/dL) indicating meaningful risk and ~250 nmol/L (100 mg/dL) identifying a substantially higher‑risk phenotype. Coronary artery calcium scoring and hsCRP ... Show More
12m 12s
Apr 21
Heart and Liver Health: Interconnectedness of CV and Hepatic Risk
ardiac and hepatic function are closely interconnected, with deterioration in one organ often accelerating disease progression in the other. Emerging evidence, including data suggesting semaglutide may slow or halt liver fibrosis progression, highlights the need to rethink how we ... Show More
10m 1s
Apr 14
Addressing Cardiovascular-Kidney-Metabolic Syndrome Health
Cardiovascular-Kidney-Metabolic (CKM) syndrome encompasses a spectrum of interconnected cardiovascular, kidney, and metabolic conditions that progress through defined stages. A five-stage CKM treatment framework emphasizes timely identification of risk factors, structured and per ... Show More
14m 48s
Feb 2025
#337 - Insulin resistance masterclass: The full body impact of metabolic dysfunction and prevention, diagnosis, and treatment | Ralph DeFronzo, M.D.
2h 26m
Jan 2025
Relationship Between Intermittent Hypoxia, COPD and Comorbidities
Dr. Amy Attaway and Dr. Dan Culver review the emerging relationship between COPD patients who have intermittent hypoxemia and an increase they have in co-morbidities and mortality. They discuss how multiple associative studies suggest that intermittent hypoxemia may impact muscul ... Show More
21m 50s
Jul 2024
382. SGLT Inhibitors: The Data Supporting SGLT Inhibition with Dr. Muthiah Vaduganathan
CardioNerds Dr. Rick Ferraro, Dr. Gurleen Kaur, and Dr. Maryam Barkhordarian discuss the evidence and data supporting SGLT inhibition for cardiovascular and kidney health outcomes with expert faculty Dr. Muthu Vaduganathan. They discuss the role of SGLT inhibitors in different po ... Show More
24m 23s
Mar 2025
Lycopene: The Unexpected Mood Booster
11m 30s
Oct 2024
393. SGLT Inhibitors: Clinical Implementation of SGLT Inhibitors with Dr. Alison Bailey
CardioNerds Drs. Jason Feinman, Gurleen Kaur, and Rick Ferraro discuss the implementation of SGLT inhibitors in clinical practice with Dr. Alison Bailey. Notes were drafted by Dr. Jason Feinman. In this episode, we discuss the implementation of SGLTi in clinical practice scenario ... Show More
19m 21s
Jan 2025
Review of the Primary Angioplasty in Myocardial Infarction Study Group trial
N Engl J Med 1993;328:673-679Background: Previous trials established that thrombolysis improves mortality in patients with acute myocardial infarction, as seen in the GISSI-1 and ISIS-2 trials. However, thrombolysis has limitations, including an increased risk of bleeding and the ... Show More
12m 26s
Feb 2025
#334 - Cardiovascular disease, the number one killer: development, biomarkers, apoB, cholesterol, brain health, and more | Tom Dayspring, M.D.
2h 17m
Apr 2025
Multiple Sclerosis - Symptoms & Interventions
Liara presents with relapsing-remitting multiple sclerosis with complaints of fatigue and difficulty walking. She reports worsening symptoms in the afternoon but denies any new relapses. Examination reveals mild spasticity in the lower limbs, decreased endurance, and poor postura ... Show More
11m 10s
Mar 2024
2500: Preventing Diabetes
Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com.
Episode 2500:
Discover how to navigate the pre-diabetes diagnosis with actionable steps from a health expert. Learn about the impor ... Show More
10m 46s
Patients with peripheral artery disease (PAD) often experience significant walking difficulties, and there are limited therapies available to improve their mobility. Investigation made through the STRIDE (Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease) trial focused on semaglutide, a drug known for promoting weight loss, reducing inflammation, and lowering the risk of heart attack or stroke, to determine if it could enhance the functional abilities of PAD patients.
In this interview, Drs. Alison Bailey and Marc Bonaca discuss how the STRIDE trial data supports the use of semaglutide for individuals with PAD and type 2 diabetes, highlighting its cardiometabolic, cardiovascular, and kidney benefits, as well as its ability to improve function, symptoms, and overall quality of life.
<p><a href= "https://peterattiamd.com/ralphdefronzo/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=250224-pod-ralphdefronzo&utm_content=250224-pod-ralphdefronzo-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/ ... Show More
<h3 id="expanderHead" data-jsid="expanderHead">Story at-a-glance</h3> <div id="expanderContent" data-jsid="expanderContent"> <ul> <li><span id="bcr_rptStory_cslStory_0">Research reveals lycopene's antidepressant properties, showing it reverses stress-induced synaptic damage and e ... Show More
<p><a href= "https://peterattiamd.com/tomdayspring7/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=250203-pod-tomdayspring7&utm_content=250203-pod-tomdayspring7-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/ ... Show More
